Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Free Report) major shareholder Eli Samaha sold 25,027 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $17.13, for a total transaction of $428,712.51. Following the sale, the insider owned 9,212,252 shares in the company, valued at approximately $157,805,876.76. This trade represents a 0.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Eli Samaha also recently made the following trade(s):
- On Wednesday, July 1st, Eli Samaha sold 37,799 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.00, for a total transaction of $642,583.00.
- On Monday, June 29th, Eli Samaha sold 273,871 shares of Theravance Biopharma stock. The shares were sold at an average price of $17.23, for a total value of $4,718,797.33.
Theravance Biopharma Price Performance
Shares of Theravance Biopharma stock opened at $16.93 on Friday. Theravance Biopharma, Inc. has a fifty-two week low of $10.82 and a fifty-two week high of $21.03. The firm has a market cap of $872.74 million, a PE ratio of 7.70 and a beta of 0.17. The business’s fifty day moving average is $16.58 and its two-hundred day moving average is $17.27.
Institutional Investors Weigh In On Theravance Biopharma
Several large investors have recently made changes to their positions in TBPH. Quarry LP purchased a new position in shares of Theravance Biopharma in the 3rd quarter valued at $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,411 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Theravance Biopharma by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 515 shares during the period. Tower Research Capital LLC TRC boosted its position in Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares during the period. Finally, CIBC Private Wealth Group LLC increased its holdings in Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 4,662 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.
Analyst Ratings Changes
A number of brokerages have issued reports on TBPH. BTIG Research lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday. Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. B. Riley Financial increased their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a report on Tuesday, April 7th. Weiss Ratings cut shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 27th. Finally, Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Theravance Biopharma presently has an average rating of “Hold” and an average price target of $21.40.
View Our Latest Stock Report on Theravance Biopharma
Theravance Biopharma Company Profile
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.
Featured Stories
- Five stocks we like better than Theravance Biopharma
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
